Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies

Murielle Mimeault, Surinder Kumar Batra

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

A growing body of experimental evidence has revealed that the highly tumorigenic cancer stem/progenitor cells endowed with stem cell-like properties might be responsible for initiation and progression of numerous aggressive epithelial cancers into locally invasive, metastatic and incurable disease states. The malignant transformation of tissue-resident adult stem/progenitor cells or their progenies into tumorigenic and migrating cancer stem/progenitor cells and their resistance to current cancer therapies have been associated with their high expression levels of specific oncogenic products and drug resistance-associated molecules. In this regard, we describe the tumorigenic cascades that are frequently activated in cancer stem/progenitor cells versus their differentiated progenies during the early and late stages of the epithelial cancer progression. The emphasis is on the growth factor signaling pathways involved in the malignant behavior of prostate and pancreatic cancer stem/progenitor cells and their progenies. Of clinical interest, the potential molecular therapeutic targets to eradicate the tumor- and metastasis-initiating cells and their progenies and develop new effective combination therapies against locally advanced and metastatic epithelial cancers are also described.

Original languageEnglish (US)
Pages (from-to)137-151
Number of pages15
JournalAnti-Cancer Agents in Medicinal Chemistry
Volume10
Issue number2
DOIs
StatePublished - Jan 1 2010

Fingerprint

Neoplastic Stem Cells
Stem Cells
Neoplasm Metastasis
Neoplasms
Therapeutics
Adult Stem Cells
Pancreatic Neoplasms
Drug Resistance
Prostatic Neoplasms
Intercellular Signaling Peptides and Proteins

Keywords

  • Combination cancer therapy
  • Epithelial cancers
  • Pancreatic cancer stem/progenitor cells
  • Prostate cancer stem/progenitor cells
  • Targeted therapy
  • Treatment resistance

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Cancer Research

Cite this

@article{66a1c176087743cea89ed1a7e3e32a25,
title = "Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies",
abstract = "A growing body of experimental evidence has revealed that the highly tumorigenic cancer stem/progenitor cells endowed with stem cell-like properties might be responsible for initiation and progression of numerous aggressive epithelial cancers into locally invasive, metastatic and incurable disease states. The malignant transformation of tissue-resident adult stem/progenitor cells or their progenies into tumorigenic and migrating cancer stem/progenitor cells and their resistance to current cancer therapies have been associated with their high expression levels of specific oncogenic products and drug resistance-associated molecules. In this regard, we describe the tumorigenic cascades that are frequently activated in cancer stem/progenitor cells versus their differentiated progenies during the early and late stages of the epithelial cancer progression. The emphasis is on the growth factor signaling pathways involved in the malignant behavior of prostate and pancreatic cancer stem/progenitor cells and their progenies. Of clinical interest, the potential molecular therapeutic targets to eradicate the tumor- and metastasis-initiating cells and their progenies and develop new effective combination therapies against locally advanced and metastatic epithelial cancers are also described.",
keywords = "Combination cancer therapy, Epithelial cancers, Pancreatic cancer stem/progenitor cells, Prostate cancer stem/progenitor cells, Targeted therapy, Treatment resistance",
author = "Murielle Mimeault and Batra, {Surinder Kumar}",
year = "2010",
month = "1",
day = "1",
doi = "10.2174/187152010790909353",
language = "English (US)",
volume = "10",
pages = "137--151",
journal = "Anti-Cancer Agents in Medicinal Chemistry",
issn = "1871-5206",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies

AU - Mimeault, Murielle

AU - Batra, Surinder Kumar

PY - 2010/1/1

Y1 - 2010/1/1

N2 - A growing body of experimental evidence has revealed that the highly tumorigenic cancer stem/progenitor cells endowed with stem cell-like properties might be responsible for initiation and progression of numerous aggressive epithelial cancers into locally invasive, metastatic and incurable disease states. The malignant transformation of tissue-resident adult stem/progenitor cells or their progenies into tumorigenic and migrating cancer stem/progenitor cells and their resistance to current cancer therapies have been associated with their high expression levels of specific oncogenic products and drug resistance-associated molecules. In this regard, we describe the tumorigenic cascades that are frequently activated in cancer stem/progenitor cells versus their differentiated progenies during the early and late stages of the epithelial cancer progression. The emphasis is on the growth factor signaling pathways involved in the malignant behavior of prostate and pancreatic cancer stem/progenitor cells and their progenies. Of clinical interest, the potential molecular therapeutic targets to eradicate the tumor- and metastasis-initiating cells and their progenies and develop new effective combination therapies against locally advanced and metastatic epithelial cancers are also described.

AB - A growing body of experimental evidence has revealed that the highly tumorigenic cancer stem/progenitor cells endowed with stem cell-like properties might be responsible for initiation and progression of numerous aggressive epithelial cancers into locally invasive, metastatic and incurable disease states. The malignant transformation of tissue-resident adult stem/progenitor cells or their progenies into tumorigenic and migrating cancer stem/progenitor cells and their resistance to current cancer therapies have been associated with their high expression levels of specific oncogenic products and drug resistance-associated molecules. In this regard, we describe the tumorigenic cascades that are frequently activated in cancer stem/progenitor cells versus their differentiated progenies during the early and late stages of the epithelial cancer progression. The emphasis is on the growth factor signaling pathways involved in the malignant behavior of prostate and pancreatic cancer stem/progenitor cells and their progenies. Of clinical interest, the potential molecular therapeutic targets to eradicate the tumor- and metastasis-initiating cells and their progenies and develop new effective combination therapies against locally advanced and metastatic epithelial cancers are also described.

KW - Combination cancer therapy

KW - Epithelial cancers

KW - Pancreatic cancer stem/progenitor cells

KW - Prostate cancer stem/progenitor cells

KW - Targeted therapy

KW - Treatment resistance

UR - http://www.scopus.com/inward/record.url?scp=77950793274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950793274&partnerID=8YFLogxK

U2 - 10.2174/187152010790909353

DO - 10.2174/187152010790909353

M3 - Review article

VL - 10

SP - 137

EP - 151

JO - Anti-Cancer Agents in Medicinal Chemistry

JF - Anti-Cancer Agents in Medicinal Chemistry

SN - 1871-5206

IS - 2

ER -